Are new antiretroviral treatments increasing the risks of clinical obesity?
There is growing evidence that the use of integrase inhibitors could lead to statistically significant increases in body weight and even clinical obesity, although it is unclear whether these changes are clinically significant. The effects of integrase inhibitors on body weight need to be analysed f...
Saved in:
Main Authors: | Andrew Hill (Author), Laura Waters (Author), Anton Pozniak (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2019-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
How can we achieve universal access to low-cost treatment for HIV?
by: Andrew M. Hill, et al.
Published: (2016) -
The impact of HIV prevalence, conflict, corruption, and GDP/capita on treatment cascades: data from 137 countries
by: Jacob Levi, et al.
Published: (2018) -
Most new HIV infections, vertical transmissions and AIDS-related deaths occur in lower-prevalence countries
by: Joe Kempton, et al.
Published: (2019) -
How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP
by: Victoria Pilkington, et al.
Published: (2018) -
New strategies for lowering the costs of antiretroviral treatment and care for people with HIV/AIDS in the United Kingdom
by: Gazzard B, et al.
Published: (2012)